Phosphorylation of ETS1 by src family kinases prevents its recognition by the COP1 tumor suppressor

Cancer Cell

Volumn 26, Issue 2, 2014, Pages 222-234

  Lu, Gang ^a   Zhang, Qing ^a   Huang, Ying ^a   Song, Jiaxi ^b   Tomaino, Ross ^b   Ehrenberger, Tobias ^c   Lim, Elgene ^a,b   Liu, Wenbin ^d   Bronson, Roderick T ^b   Bowden, Michaela ^a   Brock, Jane ^b   Krop, Ian E ^a   Dillon, Deborah A ^b   Gygi, Steven P ^b   Mills, Gordon B ^d   Richardson, Andrea L ^a,b   Signoretti, Sabina ^a,b   Yaffe, Michael B ^c   Kaelin, William G ^a,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; DASATINIB; FOCAL ADHESION KINASE; GLUTAMIC ACID; HEMATOPOIETIC CELL KINASE; IMATINIB; LAPATINIB; MESSENGER RNA; PHENYLALANINE; PROTEIN KINASE FRK; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; SERINE; SHORT HAIRPIN RNA; TAMOXIFEN; THREONINE; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR ETV5; TRANSCRIPTION FACTOR ETV6; TYROSINE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE COP1; UBIQUITIN PROTEIN LIGASE DDA1; UBIQUITIN PROTEIN LIGASE DDB1; UBIQUITIN PROTEIN LIGASE DET1; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HCT116 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SILVER STAINING; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; UBIQUITINATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; FEMALE; HCT116 CELLS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEIN C-ETS-2; SRC-FAMILY KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84905676365     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.06.026     Document Type: Article

References (56)

1. Bendinelli P., Maroni P., Matteucci E., Desiderio M.A. Comparative role of acetylation along c-SRC/ETS1 signaling pathway in bone metastatic and invasive mammary cell phenotypes. Biochim. Biophys. Acta 2011, 1813:1767-1776.
2. Bhat N.K., Thompson C.B., Lindsten T., June C.H., Fujiwara S., Koizumi S., Fisher R.J., Papas T.S. Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. Proc. Natl. Acad. Sci. USA 1990, 87:3723-3727.
3. Bosman J.D., Yehiely F., Evans J.R., Cryns V.L. Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer. Breast Cancer Res. Treat. 2010, 119:63-70.
4. Buggy Y., Maguire T.M., McGreal G., McDermott E., Hill A.D., O'Higgins N., Duffy M.J. Overexpression of the Ets-1 transcription factor in human breast cancer. Br. J. Cancer 2004, 91:1308-1315.
5. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1999, 1:193-199.
6. Charafe-Jauffret E., Ginestier C., Monville F., Finetti P., Adélaïde J., Cervera N., Fekairi S., Xerri L., Jacquemier J., Birnbaum D., Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284.
7. Clark J.P., Cooper C.S. ETS gene fusions in prostate cancer. Nat Rev Urol 2009, 6:429-439.
8. Cowley D.O., Graves B.J. Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. Genes Dev. 2000, 14:366-376.
9. Deshaies R.J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 1999, 15:435-467.
10. Elsberger B., Tan B.A., Mitchell T.J., Brown S.B., Mallon E.A., Tovey S.M., Cooke T.G., Brunton V.G., Edwards J. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?. Am. J. Pathol. 2009, 175:1389-1397.
11. Finn R.S., Dering J., Ginther C., Wilson C.A., Glaspy P., Tchekmedyian N., Slamon D.J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing invitro. Breast Cancer Res. Treat. 2007, 105:319-326.
12. Finn R.S., Bengala C., Ibrahim N., Roché H., Sparano J., Strauss L.C., Fairchild J., Sy O., Goldstein L.J. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin. Cancer Res. 2011, 17:6905-6913.
13. Hahne J.C., Okuducu A.F., Kaminski A., Florin A., Soncin F., Wernert N. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 2005, 24:5384-5388.
14. Herold C.I., Chadaram V., Peterson B.L., Marcom P.K., Hopkins J., Kimmick G.G., Favaro J., Hamilton E., Welch R.A., Bacus S., Blackwell K.L. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin. Cancer Res. 2011, 17:6061-6070.
15. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
16. Huang F., Reeves K., Han X., Fairchild C., Platero S., Wong T.W., Lee F., Shaw P., Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67:2226-2238.
17. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
18. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
19. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., von Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
20. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
21. Kurebayashi J., Kanomata N., Moriya T., Kozuka Y., Watanabe M., Sonoo H. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer 2010, 10:568.
22. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J.Clin. Invest. 2011, 121:2750-2767.
23. Levy D., Adamovich Y., Reuven N., Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell 2008, 29:350-361.
24. Lincoln D.W., Bove K. The transcription factor Ets-1 in breast cancer. Front. Biosci. 2005, 10:506-511.
25. Lindemann R.K., Braig M., Ballschmieter P., Guise T.A., Nordheim A., Dittmer J. Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int. J. Oncol. 2003, 22:799-805.
26. Lipkowitz S., Weissman A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 2011, 11:629-643.
27. Marine J.C. Spotlight on the role of COP1 in tumorigenesis. Nat. Rev. Cancer 2012, 12:455-464.
28. Matheu A., Maraver A., Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res. 2008, 68:6031-6034.
29. Mayer E.L., Krop I.E. Advances in targeting SRC in the treatmentof breast cancer and other solid malignancies. Clin. Cancer Res. 2010, 16:3526-3532.
30. Mayer E.L., Baurain J.F., Sparano J., Strauss L., Campone M., Fumoleau P., Rugo H., Awada A., Sy O., Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin. Cancer Res. 2011, 17:6897-6904.
31. Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Quantitative phosphoproteomic analysis of Tcell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci. Signal. 2009, 2:ra46.
32. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., Landen C.N., Jennings N., De Geest K., Langley R.R., Villares G., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J.Natl. Cancer. Inst 2008, 100:359-372.
33. Migliorini D., Bogaerts S., Defever D., Vyas R., Denecker G., Radaelli E., Zwolinska A., Depaepe V., Hochepied T., Skarnes W.C., Marine J.C. Cop1 constitutively regulates c-Jun protein stability and functions asa tumor suppressor in mice. J.Clin. Invest. 2011, 121:1329-1343.
34. Murphy D.A., Courtneidge S.A. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat. Rev. Mol. Cell Biol. 2011, 12:413-426.
35. Myers E., Hill A.D., Kelly G., McDermott E.W., O'Higgins N.J., Buggy Y., Young L.S. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res. 2005, 11:2111-2122.
36. Mylona E.E., Alexandrou P.T., Giannopoulou I.A., Rafailidis P.I., Markaki S., Keramopoulos A., Nakopoulou L.L. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation totumor phenotype. Cancer Detect. Prev. 2006, 30:111-117.
37. Pognonec P., Boulukos K.E., Gesquière J.C., Stéhelin D., Ghysdael J. Mitogenic stimulation of thymocytes results in the calcium-dependent phosphorylation of c-ets-1 proteins. EMBO J. 1988, 7:977-983.
38. Qin J.Y., Zhang L., Clift K.L., Hulur I., Xiang A.P., Ren B.Z., Lahn B.T. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE 2010, 5:e10611.
39. Rabault B., Ghysdael J. Calcium-induced phosphorylation of ETS1 inhibits its specific DNA binding activity. J.Biol. Chem. 1994, 269:28143-28151.
40. Reginato M.J., Mills K.R., Becker E.B., Lynch D.K., Bonni A., Muthuswamy S.K., Brugge J.S. Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol. Cell. Biol. 2005, 25:4591-4601.
41. Sánchez-Bailón M.P., Calcabrini A., Gómez-Domínguez D., Morte B., Martín-Forero E., Gómez-López G., Molinari A., Wagner K.U., Martín-Pérez J. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell. Signal. 2012, 24:1276-1286.
42. Savio M.G., Rotondo G., Maglie S., Rossetti G., Bender J.R., Pardi R. COP1D, an alternatively spliced constitutive photomorphogenic-1 (COP1) product, stabilizes UV stress-induced c-Jun through inhibition of full-length COP1. Oncogene 2008, 27:2401-2411.
43. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6:663-673.
44. Singh S., Darnay B.G., Aggarwal B.B. Site-specific tyrosine phosphorylation of IkappaBalpha negatively regulates its inducible phosphorylation and degradation. J.Biol. Chem. 1996, 271:31049-31054.
45. Span P.N., Manders P., Heuvel J.J., Thomas C.M., Bosch R.R., Beex L.V., Sweep C.G. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002, 21:8506-8509.
46. Summy J.M., Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22:337-358.
47. Sutterlüty H., Chatelain E., Marti A., Wirbelauer C., Senften M., Müller U., Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell Biol. 1999, 1:207-214.
48. Tryfonopoulos D., Walsh S., Collins D.M., Flanagan L., Quinn C., Corkery B., McDermott E.W., Evoy D., Pierce A., O'Donovan N., et al. Src:a potential target for the treatment of triple-negative breast cancer. Ann. Oncol. 2011, 22:2234-2240.
49. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 1999, 9:661-664.
50. Vetter M., Blumenthal S.G., Lindemann R.K., Manns J., Wesselborg S., Thomssen C., Dittmer J. Ets1 is an effector of protein kinase Calpha in cancer cells. Oncogene 2005, 24:650-661.
51. Vitari A.C., Leong K.G., Newton K., Yee C., O'Rourke K., Liu J., Phu L., Vij R., Ferrando R., Couto S.S., et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 2011, 474:403-406.
52. Wei W., Kaelin W.G. Good COP1 or bad COP1? Invivo veritas. J.Clin. Invest. 2011, 121:1263-1265.
53. Yu J.C., Chen J.R., Lin C.H., Zhang G., Lam P.S., Wenger K.H., Mozaffari F.B., Huang S.T., Borke J.L. Tensile strain-induced Ets-2 phosphorylation by CaMKII and the homeostasis of cranial sutures. Plast. Reconstr. Surg. 2009, 123(2, Suppl):83S-93S.
54. Zhang Y., Yan L.X., Wu Q.N., Du Z.M., Chen J., Liao D.Z., Huang M.Y., Hou J.H., Wu Q.L., Zeng M.S., et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011, 71:3552-3562.
55. Zhao J., Guan J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009, 28:35-49.
56. Zhao B., Li L., Tumaneng K., Wang C.Y., Guan K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010, 24:72-85.